Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
ATM Agreement [Member]
Private Investment In Public Equity [Member]
Segments [Axis]
Single Reportable Segment [Member]
Cash and Cash Equivalents [Axis]
Certificates of Deposit [Member]
Concentration Risk Type [Axis]
Customer Concentration Risk [Member]
Concentration Risk Benchmark [Axis]
Research And Development Costs [Member]
Customer [Axis]
Vendor And Consultant One [Member]
Vendor And Consultant Two [Member]
Vendor And Consultant Three [Member]
Vendor And Consultant Four [Member]
Accounts Payable And Accrued Expenses [Member]
Vendor One [Member]
Vendor Two [Member]
Measurement Frequency [Axis]
Fair Value, Recurring [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Antidilutive Securities [Axis]
Warrant [Member]
Share-Based Payment Arrangement, Option [Member]
Geographical [Axis]
UNITED STATES
AUSTRALIA
SINGAPORE
Sale of Stock [Axis]
July 2026 Private Placement [Member]
Pre-funded Warrant [Member]
Series F Warrant [Member]
Series G Warrant [Member]
Placement Agent Warrants [Member]
Pre Funded Warrants [Member]
Statistical Measurement [Axis]
Maximum [Member]
Legal Entity [Axis]
Wainwright [Member]
June 2025 Public Offering [Member]
Series D Warrants [Member]
Series E Warrants [Member]
Class of Stock [Axis]
Related and Nonrelated Parties [Axis]
Placement Agent [Member]
Award Date [Axis]
October 2021 [Member]
Exercisable but Unexercised Common Stock Warrants [Member]
October 2022 [Member]
October 2022-1 [Member]
October 2022-2 [Member]
November 2023 [Member]
May 21, 2020 [Member]
November 2023-1 [Member]
March 2024 [Member]
August 2024 [Member]
August 2024-1 [Member]
June 2025 [Member]
December 13, 2026 [Member]
June 2025-1 [Member]
June 2025-2 [Member]
June 27, 2013 [Member]
July 2026-1 [Member]
July 2026-2 [Member]
July 2026-3 [Member]
July 2026-4 [Member]
Award Type [Axis]
2015 Equity Incentive Plan [Member]
Title and Position [Axis]
Employees [Member]
January 2017 [Member]
January 2018 [Member]
January 2019 [Member]
January 2022 [Member]
August 2022 [Member]
September 2023 [Member]
January 2024 [Member]
September 2024 [Member]
October 2024 [Member]
January 2025 [Member]
January 2026 [Member]
September 2026 [Member]
License Agreement [Member]
Scenario [Axis]
First Commercial Sale [Member]
After First Commercial Sale [Member]
UCLA TDG [Member]
Other Commitments [Axis]
First Subject in Feasibility Study [Member]
First Subject in Pivotal Study [Member]
Pre Market Approval of Licensed Product or Licensed Method [Member]
First Commercial Sale of Licensed Product or Licensed Method [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Entity Listing, Par Value Per Share
Statement of Financial Position [Abstract]
Assets
Current Assets
Cash
Advances on research and development contract services
Prepaid insurance
Other prepaid expenses
Deferred offering costs
Interest receivable
Total current assets
Total assets
Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable and accrued expenses
Warrant liability
Total current liabilities
Total liabilities
Commitments and Contingencies
Stockholders’ Equity
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at September 30, 2026 and December 31, 2025
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 3,389,057 and 1,795,260 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Revenues
Operating expenses
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense)
Change in fair value of warrant liability
Interest income
Total other income
Net loss
Weighted average shares outstanding - basic
Weighted average shares outstanding - diluted
Loss per share - basic
Loss per share - diluted
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Fair value of vested stock options
Options issued to settle accrued bonus
Net loss
Issuance of common shares from ATM, net of costs
Issuance of common shares from ATM, net of costs, shares
Issuance of pre-funded warrants and warrants in private placement, net of costs of $358,221
Exercise of pre-funded warrants
Exercise of pre-funded warrants, shares
Proceeds from sale of common stock , pre-funded warrants and warrants in public offering, net of offering costs of $647,208
Proceeds from sale of common stock , pre-funded warrants and warrants in public offering, net of offering costs of $647,208, shares
Balance
Balance, shares
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Offering costs
Statement of Cash Flows [Abstract]
Cash flows from operating activities
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation-fair value of vested stock options
Change in fair value of warrant liability
Changes in operating assets and liabilities:
Advances on research and development contract services
Prepaid insurance
Interest receivable
Accounts payable and accrued expenses
Net cash used in operating activities
Cash flows from financing activities
Proceeds from issuance of common shares from ATM, net of costs
Proceeds from sale of common stock, pre-funded warrants and warrants in public offering, net of offering costs
Proceeds from sale of pre-funded warrants and warrants in private placement, net of offering costs
Exercise of pre-funded warrants
Deferred offering costs
Net cash provided by financing activities
Net increase in cash
Cash, beginning of period
Cash, end of period
Supplemental information
Income taxes paid
Noncash investing and financing activities
Options issued to settle accrued bonus
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Research and Development [Abstract]
Research and Development
Warrant Liability
Warrant Liability
Equity [Abstract]
Stockholders’ Equity
Common Stock Warrants
Common Stock Warrants
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation
Segment Reporting [Abstract]
Segment information
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Subsequent Events [Abstract]
Subsequent Events
Basis of Presentation
Segment Information
Use of Estimates
Macroeconomic environment and geopolitical events
Cash
Deferred Offering Costs
Research and Development Costs
Fair Value of Financial Instruments
Stock Based Compensation
Warrants
Net Loss per Common Share
Concentrations
New Accounting Standards
Schedule of Fair Value Liabilities Measured on Recurring Basis
Schedule of Warrant Liability Measured at Fair Value on a Recurring Basis Using Unobservable Level 3 Inputs
Schedule of Anti Dilutive Securities Excluded from Computation of Earnings Per Share
Summary of Research and Development Costs Based on Geographical Regions
Schedule of Warrant Activity
Schedule of Outstanding Exercisable but Unexercised Common Stock Warrants
Schedule of Stock Option Activity
Schedule of Outstanding Stock Options
Schedule of Assumptions Using Black-Scholes Option Pricing Mode
Schedule of Segment Expenses and Other Segment Items
Accumulated losses
Estimated operating expenses
Net loss
Net cash used in operating activities
Reverse stock split
AccountingPoliciesTable [Table]
Number of operating segments
Number of reporting segments
Cash, FDIC Insured Amount
Pre-funded warrants issued to purchase shares of common stock
Concentration of risk, percentage
Fair Value, Recurring and Nonrecurring [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability
Total liabilities at fair value
Beginning balance
Change in fair value of warrant liability
Ending balance
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities
Research and Development, Contract to Perform for Others [Table]
Total
Estimated remaining commitment
Warrant liability
Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]
Subsidiary, Sale of Stock [Line Items]
Number of shares sold
Purchase price per share
Sale of stock description
Gross proceeds from issuance
Net proceeds from issuance
Warrants to purchase shares of common stock
Exercise price
Warrants expire date
Placement agent fee percentage
Management fee percentage
Non-accountable expenses
Legal fees, expenses and other
Number of shares issued
Proceeds from warrant exercises
Warrant outstanding
Number of shares sold, value
Sales price commission fee percentage
Net proceeds from shares sold, value
Number of shares issued
Offering price per share
Public offering price
Warrants maturity date
Net proceeds from sale of common stock, pre-funded warrants and warrants
Number of shares issued
Number of warrants exercised
Warrants term
Schedule Of Warrant Activity
Number of Warrants, Outstanding
Weighted Average Exercise Price, Outstanding
Weighted Average Life (Years), Outstanding
Number of Warrants, Issued
Weighted Average Exercise Price, Issued
Weighted Average Life (Years), issued
Number of Warrants, Forfeited/Expired
Weighted Average Exercise Price ,Forfeited/Expired
Number of Warrants, Exercised
Weighted Average Exercise Price, Exercised
Number of Warrants, Outstanding
Weighted Average Exercise Price, Outstanding
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total outstanding warrants
Expiration date
Fair market value
Exercisable but unexercised in-the-money common stock warrants
Intrinsic value of exercisable but unexercised common stock warrants
Number of Options Outstanding, Beginning balance
Weighted Average Exercise Price, Outstanding, Beginning balance
Weighted Average Life (Years), Outstanding
Aggregate Intrinsic Value, Outstanding, Beginning balance
Number of Options, Granted
Weighted Average Exercise Price, Granted
Weighted Average Life (Years), Granted
Number of Options, Forfeited/Expired
Weighted Average Exercise Price, Forfeited/Expired
Number of Options, Exercised
Weighted Average Exercise Price, Exercised
Number of Options Outstanding, Ending balance
Weighted Average Exercise Price, Outstanding, Ending balance
Aggregate Intrinsic Value, Outstanding, Ending balance
Number of Options, Options vested and exercisable
Weighted Average Exercise Price, Options vested and exercisable
Weighted Average Exercise Price, Options vested and exercisable
Aggregate Intrinsic Value, Options vested and exercisable
Exercise Price
Number of Options
Expiration date
Risk free interest rate
Expected Volatility
Expected life (in years)
Expected dividend yield
Common stock, capital shares reserved for future issuance
Percentage of stock issued and outstanding
Share Price
Stock-based compensation expense
Common stock issued upon exercise of options
Value of shares issued for accrued bonuses settlement
Number of options exercisable
Revenue
Salaries
Insurance
Stock-based compensation
Other segment expenses
Interest income
Net loss
Number of Operating Segments
Product Liability Contingency [Table]
Product Liability Contingency [Line Items]
Maintenance fees
Licensed sales net
Royalty expenses
License commitment fee
Diligence fee
Proceeds from private placement percentage
Advances on research and development contract services.
Prepaid insurance current
Prepaid financing costs
Warrant liabilities.
Adjustments to additional paid in capital options issued to settle accrued bonus.
ATM Agreement [Member]
Stock issued during period value exercise of prefunded warrants.
Stock issued during period shares exercise of prefunded warrants.
Increase decrease in advances on research and development contract services.
Increase decrease in prepaid financing costs.
Proceeds from sale of common stock and warrants in public offering.
Options issued to settle accrued bonus.
Estimated operating expenditure.
Single Reportable Segment [Member]
Cash SPIC insured amount.
Warrants [Policy Text Block]
Schedule of Research and Development Costs Based on Geographic Areas [Table Text Block]
Warrant Liabilities [Disclosures Text Block]
Commission percentage for gross sales price per share.
Pre Funded Warrants [Member]
Series F Warrants [Member]
Series G Warrants [Member]
Placement Agent [Member]
June 2025 Public Offering [Member]
Series D Warrants [Member]
Series E Warrants [Member]
Class of warrant or right exercised.
Common Stock Warrants [Text Block]
Weighted Average Exercise Price, Outstanding.
Share based compensation arrangement by share based payment award non option equity instruments issued in period weighted average exercise price
Share based compensation arrangement by share based payment award non option equity instruments forfeitures and expriration in period weighted average exercise price.
Weighted Average Exercise Price, Exercised.
Schedule of Outstanding Vested and Unexercised Common Stock Warrants [Table Text Block]
Share based compensation arrangement by share based payment award non-option equity instruments vested and expected to vest exercisable number.
Share based compensation arrangement by share based payment award non-option equity instruments vested and expected to vest exercisable aggregate intrinsic value.
October 2021 [Member]
Exercisable but Unexercised Common Stock Warrants [Member]
October 2022 [Member]
October 2022-1 [Member]
October 2022-2 [Member]
November 2023 [Member]
November 2023-1 [Member]
March 2024 [Member]
August 2024 [Member]
August 2024-1 [Member]
June 2025 [Member]
June 2025-1 [Member]
June 2025-2 [Member]
July 2026-1 [Member]
July 2026-2 [Member]
July 2026-3 [Member]
July 2026-4 [Member]
May 21, 2020 [Member]
December 13, 2026 [Member]
June 27, 2013 [Member]
2015 Equity Incentive Plan [Member]
Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term granted.
January 2017 [Member]
January 2018 [Member]
January 2019 [Member]
January 2022 [Member]
August 2022 [Member]
September 2023 [Member]
January 2024 [Member]
September 2024 [Member]
October 2024 [Member]
January 2025 [Member]
January 2026 [Member]
September 2026 [Member]
Employees [Member]
Maintenance fees.
License agreement [Member]
Licensed sales percentage.
First Commercial Sale [Member]
After First Commercial Sale [Member]
License commitment fee.
UCLA TDG [Member]
First Subject In Feasibility Study [Member]
Pre Market Approval of Licensed Product or Licensed Method [Member]
First Commercial Sale of Licensed Product Or Licensed Method [Member]
First Subject In Pivotal Study [Member]
Diligence fee.
Percentage of amount raised in private placement.
Private Investment In Public Equity [Member]
July 2026 Private Placement [Member]
Macroeconomic Environment and Geopolitical Events [Policy Text Block]
Share based compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term 2.
Sharebased compensation arrangement by sharebased payment award non options issued weighted average remaining contractual term 2.
Proceeds from sale of common stock, pre-funded warrants and warrants in public offering, net of offering costs.
Vendor And Consultant One [Member]
Vendor And Consultant Two [Member]
Vendor And Consultant Three [Member]
Vendor And Consultant Four [Member]
Research And Development Costs [Member]
Accounts Payable And Accrued Expenses [Member]
Vendor One [Member]
Vendor Two [Member]
July 2026 Private Placement [Member]
Net proceeds from issuance of private placement.
Pre-funded Warrant [Member]
Series G Warrant [Member]
Series F Warrant [Member]
Placement Agent Warrants [Member]
Warrants expire date.
Management fee percentage.
Placement agent fee percentage.
Non accountable expenses.
Purchase fee percentage.
Wainwright [Member]
Sales price commission fee percentage.
Assets, Current
Assets [Default Label]
Liabilities, Current
Liabilities
Equity, Attributable to Parent
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Nonoperating Income (Expense)
Shares, Outstanding
IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
Increase (Decrease) in Prepaid Insurance
Increase (Decrease) in Accrued Interest Receivable, Net
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments of Financing Costs
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
OptionsIssuedToSettleAccruedBonus
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
WarrantLiabilitiesDisclosuresTextBlock
Equity [Text Block]
Common Stock Warrants [Text Block]
Commitments and Contingencies Disclosure [Text Block]
Cash and Cash Equivalents, Policy [Policy Text Block]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Derivative Liability
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
WarrantLiabilities
Weighted Average Exercise Price, Outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted-Average Remaining Contractual Term
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price
Other Income